NUREXONE BIOLOGIC INC.

Press Releases NurExone Biologic Inc.

Equities

NRX

CA67059R1091

Market Closed - Toronto S.E. Other stock markets 15:59:42 2024-06-28 EDT			5-day change	1st Jan Change
0.66 ^CAD	-2.94%		+6.45%	+123.73%

05-29	NurExone Biologic Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
04-25	NurExone Biologic Announces OTCQB Listing And DTC Eligibility	MT

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

NurExone’s ExoPTEN Being Studied as Glaucoma Treatment for US$3.4 Billion Market	06-28	AQ
On Path to First-in-Human Study, NurExone Engages Prominent Expert in Biological Drug Development	06-21	AQ
NurExone Announces Expansion of ExoPTEN Patent Coverage with Notice of Allowance for Japanese Patent Application	06-11	AQ
NurExone Announces Voting Results from 2024 Annual Meeting of Shareholders	06-04	AQ
NurExone Reports First Quarter 2024 Financial Results and Provides Corporate Update, moving forward with FDA guidelines for the Human Trials	05-29	AQ
NurExone Welcomes Biopharma Exec Dr. Ram Petter to Drive Strategic Collaborations	05-17	AQ
NurExone Biologic Inc. Announces Strategic Expansion to US Financial Markets with Approval of OTCQB Listing Application and DTC Eligibility	04-25	AQ
NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine	04-22	AQ
NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine	04-19	AQ
NurExone Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Company Update	04-02	AQ
Gross Proceeds Close of $4M CAD Generated for NurExone From Warrants Exercise	03-27	AQ
In Preparation for Expected Human Clinical Trials, NurExone Signs Agreement for Large Scale Preclinical Testing for Its Spinal Cord Injury Therapy, ExoPTEN	03-22	AQ
NurExone's Strategic Update: Submission of OTCQB Listing Application to Initiate US financial presence	03-15	AQ
NurExone establishing State-of-the-Art Research and Development Facility in Haifa, Israel	03-08	AQ
NurExone Presenting Novel Regulatory Pathways for Exosomes Therapies at Global Summit	03-01	AQ
NurExone’s Intellectual Property Portfolio Expands	02-20	AQ
NurExone Launches Licensing Efforts for ExoTherapy Platform	02-14	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Secure and Increase the Performance of your Investments with our Team of Experts at your Side

Securing my Investments

fermer